Safety and efficacy of influenza vaccination in a prospective longitudinal study of 31 children with juvenile idiopathic arthritis

Clinical and Experimental Rheumatology

Volumn 30, Issue 3, 2012, Pages 436-444

  Toplak, Nataša ^a   Šubelj, Vesna ^b   Kveder, Tanja ^c   Cucnik, Saša ^c   Prosenc, Katarina ^b   Trampuš Bakija, Alenka ^a   Todorovski, Ljupco ^d   Avcin, Tadej ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Slovenia)

^b NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Autoantibodies; Influenza vaccination; Juvenile idiopathic arthritis

Indexed keywords

ANTIBODY AGAINST EXTRACTABLE NUCLEAR ANTIGEN; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN G ANTIBODY; INFLIXIMAB; INFLUENZA VACCINE; LEFLUNOMIDE; LUPUS ANTICOAGULANT; METHOTREXATE; METHYLPREDNISOLONE; NEUTROPHIL CYTOPLASMIC ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; INJECTION SITE PAIN; JUVENILE RHEUMATOID ARTHRITIS; LONGITUDINAL STUDY; LOW DRUG DOSE; MALAISE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ARTHRITIS, JUVENILE RHEUMATOID; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA VACCINES; INFLUENZA, HUMAN; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; SLOVENIA;

EID: 84864771151     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP) CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC):General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006; 55: 24-6.
2. Heijstek MW, OTT DE Bruin LM, Bijl M et al.: EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011; 70: 1704-12.
3. Van Assen S, Agmon-Levin N, Elkayam O et al.: EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70: 414-22.
4. CDC: Prevention and control of influenza. Recommendations of the advisory committee on immunization practices (ACIP). MMWR 2008; 57: 1-60.
5. Oh CE, Lee J, Kang JH et al.: Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. Vaccine 2010; 28: 5857-63.
6. Olson NY, Lindsley CB, Page-Goertz S: Effects of influenza immunization on disease activity in juvenile rheumatoid arthritis (abstract). Arthritis Rheum 1990; 33: R33.
7. Malleson PN, Tekano JL, Scheifele DW, Weber JM: Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol 1993; 20: 1769-73.
8. Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V: Influenza vaccination in children with chronic rheumatic disease and long-term immunosuppressive therapy. Clin Exp Rheumatol 2001; 19: 589-94.
9. Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T: Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J 2011; 30: 208-11.
10. Tarjan P, Sipka S, Lakos G, Kiss E, Ujj G, Szegedi G: Influenza vaccination and the production of anti-phospholipid antibodies in patients with systemic lupus erythematosus. Scand J Rheumatol 2006; 35: 41-9.
11. Abu-Shakra M, Press J, Buskila D, Sukenik S: Influenza vaccination of patients with systemic lupus erythematosus: safety and immunogenecity issues. Autoimmun Rev 2007; 6: 543-6.
12. Ravelli A, Martini A: Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006; 24: 105-10.
13. Mack DR, Langton C, Markowitz J et al.: Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 2007; 119: 113-9.
14. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
15. Brunner HI, Lovell DJ, Finck BK, Giannini EH: Preliminary definition of disease flare in juvenile rheumatoid arthritis. J Rheumatol 2002; 29: 1058-64.
16. WHO: Manual of laboratory methods for potency testing of vaccines used in the WHO Expanded Programme on Immunisation. WHO/BLG/95; 1:71-81.
17. WHO Manual on Animal Influenza Diagnosis and Surveillance WHO/CDS/CSR/NCS/2002.5 Rev. 1
18. Benne CA, Kroon FP, Harmsen M, Tavares L, Kraaijeveld CA, De jong JC: Comparison of neutralizing and hemagglutination-inhibiting antibody responses to influenza A virus vaccination of human immunodeficiency virus-infected individuals. Clin Diagn Lab Immun 1998; 5: 114-7.
19. Ansaldi F, Bacilieri S, Durando P et al.: Cross-protection by MF59- adjuvanted influenza vaccine: neutralizing and haem agglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26: 1525-9.
20. Bunn C, Kveder T: Counterimmunoelectrophoresis and immunodiffusion for the detection of antibodies to soluble cellular antigens. In: VAN VENROOIJ WJ, MAINI RN, eds. Manual of biological markers of disease. Dordrecht: Kluwer Academic Publishers 1993; A3: 1-12.
21. Wiik A, Rasmussen N, Wieslander J: Methods to detect autoantibodies to neutrophilic granulocytes. In: MAINI RN, VAN VENROOIJ WJ (Eds.) Manual of biological markers of disease. Dodrecht: Külwer Academic Publishers 1993.
22. Avcin T, AMbrožic A, Božic B, Accetto M, Kveder T, Rozman B: Estimation of anticardiolipin antibodies, anti-beta2 glycoprotein I antibodies and lupus anticoagulant in a prospective longitudinal study of children with juvenile idiopathic arthritis. Clin Exp Rheumatol 2002; 20: 101-8.
23. Brandt JT, Triplett DA, Alving B, Scharrer I: Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/ Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 1185-90.
24. Petty RE, Southwood TR, Manners P et al.: International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
25. Fomin I, Caspi D, Levy V, Varasano N, Shalev Y, Paran D: Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNFalpha blockers. Ann Rheum Dis. 2006; 65: 191-4.
26. Elkayam O, Bashkin A, Mandelboim M et al.: The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2010; 39: 442-7.
27. Toplak N, Kveder T, Trampuš-Bakija A, Šubelj V, Cucnik S, Avcin T: Autoimmune response following annual influenza vaccination in 92 apparently healthy adults. Autoimmun Rev 2008; 8: 134-8.
28. Toplak N, Avcin T: Vaccination of healthy subjects and autoantibodies: from mice through dogs to humans. Lupus 2009; 18: 1186-91.